A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath Tumors Academic Article uri icon


MeSH Major

  • Kidney Neoplasms
  • Magnetic Resonance Imaging


  • Metastatic soft tissue sarcomas are a heterogeneous group of relatively rare malignancies. Most patients are treated with cytotoxic chemotherapy or targeted therapy in the form of tyrosine kinase inhibitors. Response rates are relatively low, and there is a need for better therapies. This clinical trial demonstrates that combining a cytotoxic therapy (dacarbazine) with an antiangiogenic small molecule (sorafenib) is feasible and associated with favorable disease-control rates; however, it also increases the potential for significant toxicity.

publication date

  • January 2018



  • Academic Article



  • eng

Digital Object Identifier (DOI)

  • 10.1634/theoncologist.2018-0160

PubMed ID

  • 30126857